SEARCH

SEARCH BY CITATION

References

  • 1
    Siltzbach LE, James DG, Neville E, Turiaf J, Battesti JP, Sharma OP et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974;57: 847852.
  • 2
    Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983;52: 525533.
  • 3
    Baughman RP, Lower EE, du Bois R. Sarcoidosis. Lancet 2003;361: 11111118.
  • 4
    Kern DG, Neill MA, Wrenn DS, Varone JC. Investigation of a unique time-space cluster of sarcoidosis in firefighters. Am Rev Respir Dis 1993;148: 974980.
  • 5
    Parkes SA, Baker SB, Bourdillon RE, Murray CR, Raskit M. Epidemiology of sarcoidosis in the Isle of Man: 1. A case–control study. Thorax 1987;42: 420426.
  • 6
    Hills SE, Parkes SA, Baker SB. Epidemiology of sarcoidosis in the Isle of Man: 2. Evidence of space-time clustering. Thorax 1987;42: 427430.
  • 7
    Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA et al. ACCESS Research Group. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis(ACCESS). Am J Respir Crit Care Med 2001;164: 20852091.
  • 8
    Grunewald J, Eklund A, Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 2004;169: 696702.
  • 9
    Spagnolo P, Renzoni EA, Wells AU, Sato H, Grutters JC, Sestini P et al. C-C chemokine receptor 2 and sarcoidosis: association with Löfgren's syndrome. Am J Respir Crit Care Med 2003;168: 11621166.
  • 10
    Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336: 12241234.
  • 11
    Rybicki BA, Major M, Popovitch J, Maliarik MJ Jr, Ianuzzi MC. Racial differences in sarcoidosis incidence: a five year study in a health maintenance organization. Am J Epidemiol 1997;145: 234241.
  • 12
    Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. Am Rev Respir Dis 1984;130: 2932.
  • 13
    ATS/ERS/WASOG Committee. Statement on sarcoidosis. Am J Respir Crit Care Med 1999;160: 736755.
  • 14
    Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA et al. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164: 18851889.
  • 15
    Lynch JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clinics in Chest Medicine 1997;18: 755785.
  • 16
    De Remee RA, Andersen HA. Sarcoidosis: a correlation of dyspnea with roentgenographic stage and pulmonary function. Mayo Clin Proc 1974;49: 742745.
  • 17
    Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J 1993;6: 349353.
  • 18
    Vidal M, Ramama CV, Dusso AS. Stat1-vitamin D receptor interactions antagonize 1, 25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol 2002;22: 27772787.
  • 19
    Reich JR. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002;121: 3239.
  • 20
    Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18: 7074.
  • 21
    Robinson DS, Richeldi L, Saltini C, DuBois RM. Granulomatous processes. In: CrystalRG, WestJB, editors. The lung. Scientific foundations, 2nd edn. New York: Raven press, 1997: 23952409.
  • 22
    Soler P, Basset F, Bernaudin JF, Chrétien J. Morphology and distribution of the cells of a sarcoid granuloma: ultrastructural study of serial sections. Ann NY Acad Sci 1976;278: 147160.
  • 23
    Conron M, du Bois RM. Immunological mechanisms in sarcoidosis. Clin Exp Allergy 2001;31: 543554.
  • 24
    Agostini C, Facco M, Chilosi M, Semenzato G. Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation. Microsc Res Techniq 2001;53: 278287.
  • 25
    Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987;135: 747760.
  • 26
    Tsuchiya Y, Nakao A, Komatsu T, Yamamoto M, Shimokata K. Relationship between gallium 67 citrate scanning and transferrin receptor expression in lung diseases. Chest 1992;102: 530534.
  • 27
    Kwekkeboom DJ, Krenning EP, Kho S, Breeman WAP, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998;25: 12841292.
  • 28
    Soler P, Boussaud V, Moreau J, Bergeron A, Bonnette P, Hance AJ et al. In situ expression of B7 and CD40 costimulatory molecules by normal human lung macrophages and epithelioid cells in tuberculoid granulomas. Clin Exp Immunol 1999;116: 332339.
  • 29
    Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003;253: 1830.
  • 30
    Bergeron A, Bonay M, Kambouchner M, Lecossier D, Riquet M, Soler P et al. Cytokine patterns in tuberculous and sarcoidosis granulomas. Correlations with histopathologic features of the granulomatous response. J Immunol 1997;159: 30343043.
  • 31
    Larousserie F, Pflantz S, Coulomb-L'Herminé A, Brousse N, Kastelein R, Devergne O. Expression of IL-27 in human Th1-associated grnulomatous diseases. J Pathol 2004;202: 164171.
  • 32
    Verleden GM, du Bois RM, Bouros D, Drent M, Millar A, Müller-Quernheim J et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J 2001;32: 17s29s.
  • 33
    du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med 2003;253: 417.
  • 34
    Vassilakis DA, Sourvinos G, Markatos M, Psathakis K, Spandidos DA, Siafakas NM et al. Microsatellite DNA instability and loss of heterozygosity in pulmonary sarcoidosis. Am J Respir Crit Care Med 1999;160: 17291733.
  • 35
    Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999;160: 16681672.
  • 36
    James DG, Williams WJ. Kveim–Siltzbach test revisited. Sarcoidosis 1991;8: 69.
  • 37
    Burke WM, Keogh A, Maloney PJ, Delprado W, Bryant DH, Spratt P. Transmission of sarcoidosis via cardiac transplantation. Lancet 1990;336: 1579.
  • 38
    Heyll A, Meckenstock G, Aul C, Sohngen D, Borchard F, Hadding U et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;14: 161164.
  • 39
    Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988;334: 395402.
  • 40
    Hance AJ. The role of mycobacteria in the pathogenesis of sarcoidosis. Semin Respir Infect 1998;13: 197205.
  • 41
    Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura T et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 2002;40: 198204.
  • 42
    Gazouli M, Ikonomopoulos J, Trigidou R, Foteinou M, Kittas C, Gorgoulis V. Assessment of mycobacterial, propionibacterial, and human herpesvirus 8 DNA in tissues of Greek patients with sarcoidosis. J Clin Microbiol 2002;40: 30603063.
  • 43
    Hiramatsu J, Katakoa M, Nakata Y, Okazaki K, Tada S, Tanimoto M et al. Propionibacterium acnes DNA detected in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003;20: 197203.
  • 44
    Nishiwaki T, Yoneyama H, Eishi Y, Matsuo N, Tatsumi K, Kimura H et al. Indigenous pulmonary Propionibacterium acnes primes the host in the development of sarcoid-like pulmonary granulomatosis in mice. Am J Pathol 2004;165: 631639.
  • 45
    Valeyre D, Soler P, Clerici C, Pre J, Battesti JP, Georges R et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis and evolution of sarcoidosis. Thorax 1988;43: 516524.
  • 46
    Mayock RL, Bertrand P, Morrison CE. Manifestations of sarcoidosis: analysis of 145 patients with a review of nine series selected from the literature. Am J Med 1963;35: 6789.
  • 47
    Winterbauer RH, Belic N, Moores KD. A clinical interpretation of bilateral hilar adenopathy. Ann Intern Med 1973;78: 6571.
  • 48
    Bein ME, Putman CE, McLoud TC, Mink JH. A reevaluation of intrathoracic lymphadenoathynin saroidosis. AJR 1978;131: 409413.
  • 49
    Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the John Hopkins Hospital. Medicine (Baltimore) 1999;78: 65111.
  • 50
    Baumann MH, Strange C, Sahn SA. Do chest radiographic findings reflect the clinical course of patients with sarcoidosis during corticosteroid withdraw. AJR 1990;154: 481484.
  • 51
    De Remee RA. Sarcoidosis. A concise review for primary-care physicians. Mayo Clin Proc 1995;70: 177181.
  • 52
    Rockoff SD, Rohadgi P. Unusual manifestations of thoracic sarcoidosis. AJR 1985;144: 513528.
  • 53
    Lewis MI, Horak DA. Airway obstruction in sarcoidosis. Chest 1987;92: 582584.
  • 54
    Lamberto C, Nunes H, Le Toumelin P, Duperron F, Valeyre D, Clerici C. Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis: relation to exercise gas exchange. Chest 2004;125: 20612068.
  • 55
    Levinson RS, Metzger LF, Stanley NN et al. Airway function in sarcoidosis. Am J Med 1977;62: 5159.
  • 56
    Hadfield JW, Page RL, Flower CDR, Stark JE. Localised airway narrowing in sarcoidosis. Thorax 1982;37: 443447.
  • 57
    Costabel U. Sensitivity and specificity of BAL findings in sarcoidosis. Sarcoidosis 1992;9(Suppl. 1):211214.
  • 58
    Brauner MW, Grenier P, Mompoint D, Lenoir S, de Cremoux H. Pulmonary sarcoidosis: evaluation with high-resolution CT. Radiology 1989;172: 467471.
  • 59
    Müller NL, Kig P, Miller RR. The CT findings of pulmonary sarcoidosis: analysis of 25 patients. AJR 1989;152: 11791182.
  • 60
    Murdoch J, Müller L. Pulmonary sarcoidosis: changes on follow-up CT. AJR 1992;159: 473477.
  • 61
    Brauner MW, Lenoir S, Grenier P, Cluzel P, Battesti JP, Valeyre D. Pulmonary sarcoidosis: CT assessment of lesion reversibility. Radiology 1992;182: 349354.
  • 62
    Abehsera M, Valeyre D, Grenier P, Jaillet H, Battesti JP, Brauner MW. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR 2000;174: 17511757.
  • 63
    Hansell DM, Milne DG, Wilsher ML, Wells AU. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology 1998;209: 697704.
  • 64
    Grenier P, Chevret S, Beigelman S, Brauner MW, Chastang C, Valeyre D. Chronic diffuse infiltrative lung disorders: determination of the diagnostic value of clinical data, chest radiography and CT using Bayesian analysis. Radiology 1994;191: 383390.
  • 65
    Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 1987;59: 896900.
  • 66
    Spickett GP, Farrant J, North ME, Zhang JG, Morgan L, Webster DB. Common variable immunodeficiency: how many diseases. Immunology Today 1997;18: 325328.
  • 67
    Sharma OP. Airway obstruction in sarcoidosis. Chest 1978;73: 67.
  • 68
    Rizzato G, Pezzano A, Sala G et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983;64: 121128.
  • 69
    Davies J, Nellen M, Goodwin JF. Reversible pulmonary hypertension in sarcoidosis. Postgrad Med J 1982;58: 282285.
  • 70
    Grutters JC, Sato H, Welsh KI, du Bois RM. The importance of sarcoidosis genotype to lung phenotype. Am J Respir Cell Mol Biol 2003;29: S59S62.
  • 71
    Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994;149: 893898.
  • 72
    Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51: 238247.
  • 73
    Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997;111: 623631.
  • 74
    Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 1998;15: 5258.
  • 75
    Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis 1979;60: 215221.
  • 76
    James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet 1967;2: 526528.
  • 77
    Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med 1987;87: 496499.
  • 78
    Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999;116: 424431.
  • 79
    Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002;121: 2431.
  • 80
    Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973;107: 609614.
  • 81
    Baughman RP. Therapeutic options for sarcoidosis: new and old. Curr Opin Pulm Med 2002;8: 464469.
  • 82
    Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis. JAMA 2002;287: 13011307.
  • 83
    Reich JM. Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003;20: 227234.
  • 84
    Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids. The six phases of treatment. Chest 1999;115: 11581165.
  • 85
    Seitzer U, Gerdes J, Muller-Quernheim J. Evidence for disease phenotype associated haplotypes (DR.TNF) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18: 279283.
  • 86
    Grutters JC, Sato H, Pantelidis P, Lagan AL, McGrath DS, Lammers JW et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002;165: 11191124.
  • 87
    Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115: 3642.
  • 88
    Fehrenbach H, Zissel G, Goldmann T, Tschernig T, Vollmer E, Pabst R et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J 2003;21: 421428.
  • 89
    Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990;142: 12681271.
  • 90
    Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999;14: 11171122.
  • 91
    Pueringer RJ, Schwartz DA, Dayton CS, Gilbert SR, Hunninghake GW. The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest 1993;103: 832838.
  • 92
    Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997;156: 15861592.
  • 93
    Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19: 185190.
  • 94
    Baughman RP, Iannuzzi MC, Lower EE, Moller DR, Balkissoon RC, Winget DB et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19: 198204.
  • 95
    Du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999;13: 13451350.
  • 96
    Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on pulmonary sarcoidosis. Eur Respir J 1995;8: 682688.
  • 97
    Erkkila S, Froseth B, Hellstrom PE, Kaltiokallio K, Taskinen E, Viljanen A et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988;5: 106110.
  • 98
    Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999;160: 192197.
  • 99
    Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990;23: 487489.
  • 100
    Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 1989;111: 437438.
  • 101
    Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998;55: 12481254.
  • 102
    Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999;54: 742746.
  • 103
    Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990;299: 153157.
  • 104
    Baughman RP, Lower EE. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995;155: 846851.
  • 105
    Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977;97: 213216.
  • 106
    Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991;24: 451454.
  • 107
    Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999;106: 111118.
  • 108
    Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108: 11341139.
  • 109
    Maust HA, Foroozan R, Sergott RC, Niazi S, Weibel S, Savino PJ. Use of methotrexate in sarcoid-associated optic neuropathy. Ophthalmology 2003;110: 559563.
  • 110
    Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997;157: 18641868.
  • 111
    Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995;52: 875879.
  • 112
    Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn MF, Malaise MG. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995;34: 642644.
  • 113
    Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17: 6066.
  • 114
    Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber FL. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med 2003;163: 615620.
  • 115
    Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis 1996;55: 273275.
  • 116
    Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16: 8792.
  • 117
    Pacheco Y, Marechal C, Marechal F, Biot N, Perrin Fayolle M. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 1985;2: 107113.
  • 118
    Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991;8: 3541.
  • 119
    Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med 1997;156: 13711376.
  • 120
    Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003;124: 20232026.
  • 121
    Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003;148: 147148.
  • 122
    Nguyen YT, Dupuy A, Cordoliani F, Vignon-Pennamen MD, Lebbe C, Morel P et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004;50: 235241.
  • 123
    Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002;102: 225236.
  • 124
    Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32: 866869.
  • 125
    Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002;122: 227232.
  • 126
    Walter MC, Lochmuller H, Schlotter-Weigel B, Meindl T, Muller-Felber W. Successful treatment of muscle sarcoidosis with thalidomide. Acta Myol 2003;22: 2225.
  • 127
    Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001;135: 2731.
  • 128
    Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology 2002;59: 16601661.
  • 129
    Mallbris L, Ljungberg A, Hedblad MA, Larsson P, Stahle-Backdahl M. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2003;48: 290293.
  • 130
    Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003;60: 426430.
  • 131
    Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124: 20282031.
  • 132
    Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 2003;48: 35423543.
  • 133
    Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 2004;150: 146149.
  • 134
    Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004;63: 318320.
  • 135
    Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003;30: 18641867.
  • 136
    Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124: 177185.
  • 137
    Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997;155: 16651669.
  • 138
    Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001;137: 6973.
  • 139
    Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis. Sarcoidosis 1991;8: 2934.
  • 140
    Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003;163: 26192624.
  • 141
    Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997;61: 382385.
  • 142
    Iles PB. Multiple bronchial stenoses: treatment by mechanical dilatation. Thorax 1981;36: 784786.
  • 143
    Ball JB, Delaney JC, Evans CC, Donnelly RJ, Hind CR. Endoscopic bougie and balloon dilatation of multiple bronchial stenoses: 10 year follow up. Thorax 1991;46: 933935.
  • 144
    Barbers RG. Role of transplantation (lung, liver, and heart) in sarcoidosis. Clin Chest Med 1997;18: 865874.
  • 145
    Judson MA. Lung transplantation for pulmonary sarcoidosis. Eur Respir J 1998;11: 738744.
  • 146
    Walker S, Mikhail G, Banner N, Partridge J, Khaghani A, Burke M et al. Medium term results of lung transplantation for end stage pulmonary sarcoidosis. Thorax 1998;53: 281284.
  • 147
    Shorr AF, Helman DL, Davies DB, Nathan SD. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest 2004;125: 990996.
  • 148
    Hadjiliadis D, Sporn TA, Perfect JR, Tapson VF, Davis RD, Palmer SM. Outcome of lung transplantation in patients with mycetomas. Chest 2002;121: 128134.
  • 149
    Collins J, Hartman MJ, Warner TF, Muller NL, Kazerooni EA, McAdams HP et al. Frequency and CT findings of recurrent disease after lung transplantation. Radiology 2001;219: 503509.
  • 150
    Moller DR. Treatment of sarcoidosis – from a basic science point of view. J Intern Med 2003;253: 3140.